Baillie Gifford & Co. Sells 823,027 Shares of DexCom, Inc. $DXCM

Baillie Gifford & Co. reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 4.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,882,168 shares of the medical device company’s stock after selling 823,027 shares during the period. DexCom makes up about 0.8% of Baillie Gifford & Co.’s investment portfolio, making the stock its 25th biggest position. Baillie Gifford & Co. owned approximately 4.05% of DexCom worth $1,068,711,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Andra AP fonden bought a new position in shares of DexCom in the 2nd quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of DexCom during the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. raised its holdings in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new stake in DexCom during the third quarter valued at about $29,000. Finally, Sound Income Strategies LLC increased its position in DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after buying an additional 285 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 1.4%

DXCM opened at $72.86 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock’s 50 day moving average price is $66.41 and its 200-day moving average price is $71.24. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The stock has a market cap of $28.42 billion, a price-to-earnings ratio of 40.48, a P/E/G ratio of 1.33 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the firm earned $0.45 earnings per share. The business’s revenue was up 21.6% on a year-over-year basis. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DXCM shares. Leerink Partners reiterated an “outperform” rating and issued a $92.00 price target on shares of DexCom in a research note on Tuesday, December 16th. Evercore ISI began coverage on shares of DexCom in a research report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 target price for the company. Sanford C. Bernstein reiterated an “outperform” rating and issued a $86.00 price target (up previously from $84.00) on shares of DexCom in a research note on Friday, January 9th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Finally, TD Cowen lowered their target price on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.30.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach acquired 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the acquisition, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. The trade was a 5.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the transaction, the director owned 37,994 shares in the company, valued at approximately $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.